Pfizer Strategist Andrew Baum Shifts to Senior Advisor Role Under Bourla
Pfizer Chief Strategy and Innovation Officer Andrew Baum is stepping down from his executive position to serve as a senior strategic advisor to CEO Albert Bourla. Baum, a former top-tier equity research analyst, joined the pharmaceutical giant in 2024 to provide an outside-in perspective on the company’s portfolio. He will support the executive team through the end of the year before departing the company entirely. Analysts view the move as part of a broader “operational simplification” as the New York-based drugmaker streamlines its leadership structure following a period of massive post-pandemic realignment…










